A vaccine for Covid 19 from the University of Oxford and AstraZeneca has been approved for use in the UK.
The vaccine, developed by scientists from Oxford University and identified as a “game changer,” was given the green light by the Regulatory Agency for Medicines and Healthcare Products (MHRA).
For a mass launch, this paves the way.
100 million doses of vaccine were requested by the United Kingdom-enough to vaccinate 50 million people.
“The government today accepted the recommendation of the Medicines and Healthcare Products Regulatory Agency (MHRA) to approve Oxford University/Covid-19 AstraZeneca’s vaccine for use,” a spokesman for the Department of Health and Social Care said.
“This follows rigorous clinical trials and a thorough analysis of the data by MHRA experts, who concluded that the vaccine met their strict standards for safety, quality and efficacy.”
Coronavirus: Scottish care homes at risk of Covid infection spread
Data reported in the medical journal The Lancet in early December showed that in a sample of 4,440 people who received two regular doses of the vaccine, the vaccine was 62 percent successful in preventing Covid-19, compared with 4,455 people who received a placebo.
There was 90 percent safety against Covid-19 in 1,367 people who received a half first dose of the vaccine followed by a full second dose, compared to a control group of 1,374 people.
The comprehensive findings from clinical trials affecting more than 20,000 individuals provide the full data from the Lancet peer-reviewed report.
Ten of the individuals who received placebo were hospitalized with coronavirus, including two with serious covidus, which resulted in one death.
There were, however, no hospitalizations or serious cases among those who received the vaccine.
The result of an accidental dosing error was the half dose followed by the full dose.
The MHRA was, however, made aware of the incident, and the vaccine’s clinical trials were allowed to proceed.
Since Margaret Keenan became the first person in the world to receive the vaccine outside of a clinical trial, more than 600,000 people in the UK have been vaccinated.
The approval of the Ocford vaccine would lead to potential mass vaccinations, and the vaccine can be stored in a regular refrigerator, unlike the Pfizer-BioNTech vaccine, which must be stored ultra-cold at -70 ° C.
AstraZeneca CEO Pascal Soriot suggested in an interview with The Sunday Times that more data submitted to the regulator indicates that the vaccine will equal the 95% efficacy of Pfizer/BioNTech and Moderna vaccines.
“We believe we have found the winning formula and how to achieve efficacy that rivals all others after two doses,” he said.
Scotland’s Coronavirus: Nicola Sturgeon gives plea to Hogmanay Covid rules
“The vaccine was identified as a “game changer” on Monday by Calum Semple, professor of epidemic medicine at the University of Liverpool and member of the Scientific Advisory Group for Emergencies (Sage), but said it will take until the summer to vaccinate enough people for herd immunity – when the virus is struggling to spread.
“To achieve herd immunity in the population, probably 70 percent to 80 percent of the population will have to be vaccinated, and that, I fear, will take until the summer,” he said.